Evaluation of the efficacy and safety of microdystrophin replacement therapy with delandistrogene moxeparvovec in patients with progressive Duchenne muscular dystrophy in real-life clinical practice
Open Access
- 30 April 2026
- journal article
- Published by Publishing House ABV Press in Russian Journal of Child Neurology
- Vol. 21 (1)
Abstract
Progressive Duchenne muscular dystrophy is a severe progressive X-linked hereditary disease caused by mutations in the DMD gene encoding the dystrophin protein. The disease is characterized by early onset of muscle weakness in the proximal limbs, loss of the ability to walk independently, followed by damage to respiratory and cardiac functions, and premature death of patients in the second or third decade of life. Until recently, patients were prescribed only symptomatic treatment aimed at slowing down the progression of the disease. Currently, several pathogenetic drugs have appeared aimed at restoring the synthesis of the dystrophin protein (microdystrophin). One of them, delandistrogen moxparvovec, is gene therapy drug based on a recombinant adeno-associated virus (AAVhr74). The article presents the experience of using Delandistrogen moxparvovec in 17 patients with Duchenne muscular dystrophy aged 5 years 8 months to 9 years and 1 months. Preliminary data indicate a possible slowdown in the progression of the disease, which is manifested in stabilization or improvement of motor functions. In all patients, the use of this drug was safe, there were no adverse events associated with this therapy.Keywords
This publication has 11 references indexed in Scilit:
- Duchenne muscular dystrophy, one of the most complicated diseases for gene therapyJournal of Translational Genetics and Genomics, 2025
- AAV gene therapy for Duchenne muscular dystrophy: the EMBARK phase 3 randomized trialNature Medicine, 2024
- Delandistrogene Moxeparvovec Gene Therapy in Ambulatory Patients (Aged ≥4 to <8 Years) with Duchenne Muscular Dystrophy: 1‐Year Interim Results from Study SRP‐9001‐103 (ENDEAVOR)Annals of Neurology, 2023
- Long‐term safety and functional outcomes of delandistrogene moxeparvovec gene therapy in patients with Duchenne muscular dystrophy: A phase 1/2a nonrandomized trialMuscle & Nerve, 2023
- Micro-dystrophin gene therapy demonstrates long-term cardiac efficacy in a severe Duchenne muscular dystrophy modelMolecular Therapy - Methods & Clinical Development, 2023
- Exon-Skipping in Duchenne Muscular DystrophyJournal of Neuromuscular Diseases, 2021
- Duchenne muscular dystrophyNature Reviews Disease Primers, 2021
- Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and neuromuscular, rehabilitation, endocrine, and gastrointestinal and nutritional managementThe Lancet Neurology, 2018
- The burden, epidemiology, costs and treatment for Duchenne muscular dystrophy: an evidence reviewOrphanet Journal of Rare Diseases, 2017
- A systematic review and meta-analysis on the epidemiology of Duchenne and Becker muscular dystrophyNeuromuscular Disorders, 2014